JUL 14, 2020 3:18 PM PDT

What Makes A Strong Antibody Response to Coronavirus

WRITTEN BY: Kara Marker

Scientists all over the world are racing to develop a vaccine that effectively and safely prompts protective immunity to SARS-CoV-2, commonly known simply as “the coronavirus” or “the novel coronavirus.” In a new finding from the Scripps Research Institute, researchers found something that many antibodies against the coronavirus have in common: a gene, IGHV3-53.

Triggering the immune system to produce protective antibodies is a fundamental aspect of a successful vaccine candidate. In their study, researchers analyzed nearly 300 anti-coronavirus antibodies extracted from the blood of individuals recovering from COVID-19, the illness caused by the coronavirus. They found that the antibody gene IGHV3-53 was majorly involved in encoding many of these antibodies.

Using an imaging technique called X-ray crystallography, researchers then took images of two IGHV3-53-encoded antibodies as they attached to their target site on the coronavirus, the infamous “viral spike protein” that gives the coronavirus its namesake. The binding of an antibody to this target site prevents the virus from binding human cells and beginning the infection process, thus protected the individual from disease.

These images, providing “atomic-structure details,” provide a roadmap for “vaccine designers” by depicting the exact mechanisms by which antibodies bind the viral target site on the coronavirus. For vaccine designers, this roadmap leads them right to their destination: how to produce therapies that prevent the virus from launching an infection inside a vaccinated person’s body. The roadmap could also be applicable in antiviral drug development, where the same information could be used to design treatments for existing infections.

"This type of antibody has been isolated frequently in studies of COVID-19 patients, and we can now understand the structural basis for its interaction with SARS-CoV-2," explained senior author Ian Wilson, DPhil.

Other research studies have found that IGHV3-53-encoded antibodies can also be present in the blood of seemingly healthy individuals. In theory, a vaccine created to prevent COVID-19 could work by enhancing these antibody levels that already exist, providing protection from disease by the coronavirus.

"Coronaviruses have been around for hundreds to thousands of years, and one can imagine that our immune system has evolved in such a way that we carry antibodies like these that can make a powerful response right off the bat,” Wilson explained.

These new research findings will help scientists determine the ingredients of a vaccine that could build protective immunity from COVID-19. In the words of co-author Dennis Burton, PhD, the results provide “important inspiration for effective COVID-19 vaccine design.”

As of Tuesday, July 14, 2020, there have been at least 3.4 million cases of coronavirus infection and 135,916 deaths from COVID-19 in the United States, according to the New York Times.

Sources: Scripps Research Institute, Science, New York Times

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JAN 26, 2021
Immunology
COVID Vaccine Reactions: You're As Likely to Be Struck by Lightning
JAN 26, 2021
COVID Vaccine Reactions: You're As Likely to Be Struck by Lightning
In a period of just over three weeks, over four million people received Moderna’s COVID-19 vaccine. Out of all the ...
FEB 04, 2021
Clinical & Molecular DX
Neurological and Psychiatric Aftershocks of the Pandemic
FEB 04, 2021
Neurological and Psychiatric Aftershocks of the Pandemic
One in eight COVID-19 survivors have received a diagnosis of a neurological or psychiatric condition in the year followi ...
MAR 23, 2021
Immunology
Assay Detects Antibodies in Asymptomatic COVID Carriers
MAR 23, 2021
Assay Detects Antibodies in Asymptomatic COVID Carriers
It is estimated that around one in five people infected with SARS-CoV-2 will not show any infection symptoms. Some of th ...
JUN 05, 2021
Coronavirus
Newly-Named Coronavirus Variant Causes Concern
JUN 05, 2021
Newly-Named Coronavirus Variant Causes Concern
WHO has decided to create a new naming system for coronavirus variants for several reasons. The names will now be based ...
JUN 11, 2021
Cannabis Sciences
Does Cannabis Interact with the COVID Vaccine?
JUN 11, 2021
Does Cannabis Interact with the COVID Vaccine?
As of June 10th 2021, 43% of people in the US aged 12 and over have been fully vaccinated for COVID-19, with 5 ...
JUL 18, 2021
Drug Discovery & Development
COVID-19 Antibiotic No More Effective than Placebo
JUL 18, 2021
COVID-19 Antibiotic No More Effective than Placebo
Azithromycin, a broad-spectrum antibiotic commonly used to prevent symptoms of COVID-19 in non-hospitalized patients, do ...
Loading Comments...